This week on Pharm5:
- Monkeypox vaccine for work-related exposure to orthopoxvirus
- Lymphoma drug Ukoniq (umbralisib) loses FDA approval
- Psychedelic, synthetic psylocibin tested for use in severe depression
- Expanding uses for antineoplastic agent azacitidine
- Addendum to the 2022 Standards of Medical Care in Diabetes
References:
- Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. Centers for Disease Control and Prevention. https://bit.ly/3MkpYtq. Published May 27, 2022. Accessed June 2, 2022.
- FDA withdraws lymphoma drug approval after investigation. Medscape. https://wb.md/3GJIMRw. Published June 1, 2022. Accessed June 2, 2022.
- Melville NA. Psilocybin effective up to 12 weeks in severe depression. Medscape. https://wb.md/3xeigg5. Published June 2, 2022. Accessed June 2, 2022.
- DRUGS@FDA: FDA-approved drugs. accessdata.fda.gov. https://bit.ly/3Mr6kvT. Accessed June 2, 2022.
- Center for Drug Evaluation and Research. FDA approves azacitidine. U.S. Food and Drug Administration. https://bit.ly/3xdSoRw. Published May 20, 2022. Accessed June 2, 2022.
- FDA approves Ivosidenib/Azacitidine for certain patients with newly diagnosed AML. The ASCO Post. https://bit.ly/3GHaoGY. Published May 26, 2022. Accessed June 2, 2022.
- Addendum. 10. cardiovascular disease and risk management: Standards of medical care in diabetes–2022. diabetes care 2022;45(suppl. 1):S144–S174. Diabetes Care. May 2022. doi:10.2337/dc22-ad08
- Aspirin use to prevent cardiovascular disease: Preventive medication. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce. https://bit.ly/3m93gtn. Published April 26, 2022. Accessed Jun 2, 2022.
